AUTHORS
Andrew T Kuykendall, MD, Aniket Bankar, MD, MSc, DM, MBBS2, Kristen Pettit, MD3, Joseph Shatzel, MD4, Jiri Mayer, MD5, Valentín García Gutiérrez I, MD6, Alessandro Lucchesi, MD, PhD7, Abdulraheem Yacoub, MD8, Harinder Gill, MBBS, MD9, Daniel Sasca, MD10, Lindsay Rein, MD11, Samah Alimam, MD12, Arturo Molina, MD, MS13, Phil Dinh14, Ziji Yu15, Frank Campana, MD16, Alicia Cerretani, PharmD17, Naveen Pemmaraju, MD18, Joseph Scandura, MD, PhD19
AFFILIATIONS
1 Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, United States
2 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
3 University of Michigan, Ann Arbor, Michigan, United States
4 Oregon Health & Science University, Portland, Oregon, United States
5 University Hospital Brno and Masaryk University, Brno, Czech Republic
6 Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
7 IRCCS Istituto Romagnolo per lo Studio e la Cura dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
8 University of Kansas Cancer Center, Westwood, Kansas, United States
9 The University of Hong Kong, Hong Kong, Hong Kong
10 University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
11 Duke University School of Medicine / Duke Cancer Institute, Duke University, Durham, North Carolina, United States
12 University College London Hospitals NHS Foundation Trust, London, United Kingdom
13 Protagonist Therapeutics, Inc., Newark, California, United States
14 Protagonist Therapeutics, Inc., Newark, California, United States
15 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
16 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
17 Takeda Pharmaceuticals America, Inc., Cambridge, Massachusetts, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 Weill Cornell Medicine, New York, New York, United States
ABSTRACT
Background: Polycythemia vera (PV) is defined by erythrocytosis; maintaining hematocrit (Hct) <45% is a key treatment goal to reduce thrombotic risk. Patients (pts) with PV may have leukocytosis and/or thrombocytosis. In the Phase 3 VERIFY study (NCT05210790), rusfertide, a first-in-class, self-administered, subcutaneous peptide mimetic of the endogenous hormone hepcidin, reduced erythrocytosis vs placebo (PBO) in pts with PV. This subgroup analysis investigated the effect of rusfertide in pts with erythrocytosis with/without baseline (BSL) leukocytosis or thrombocytosis.
Methods: Pts with PV requiring frequent phlebotomy (PHL) with/without cytoreductive therapy (CRT) were randomized 1:1 to receive rusfertide or PBO from BSL to Week (Wk) 32. The primary endpoint was clinical response (absence of PHL eligibility) from Wks 20–32. Key secondary endpoints included mean number of PHLs and Hct control (Hct <45% with one Hct ≥45% permitted) from BSL to Wk 32. This post hoc analysis evaluated rusfertide vs PBO according to BSL concurrent treatment: PHL only or PHL+CRT, stratified by BSL platelet (PLT) count (>400 x 10⁹/L [high] and ≤400 x10⁹/L [normal]), and white blood cell (WBC) count (>10 x10⁹/L [high] and ≤10 x 10⁹/L [normal]).
Results: Overall, 147 pts were randomized to rusfertide and 146 to PBO. Among pts in the PHL only group, 101 pts had high BSL PLT (rusfertide, n=50; PBO, n=51) and 30 had normal BSL PLT (rusfertide, n=15; PBO, n=15); 57 pts had high BSL WBC (rusfertide, n=26; PBO, n=31), and 74 had normal BSL WBC (rusfertide, n=39; PBO, n=35). Among pts receiving PHL+CRT, 44 pts had high BSL PLT (rusfertide, n=20; PBO, n=22), and 120 had normal BSL PLT (rusfertide, n=62; PBO, n=58); 34 pts had high BSL WBC (rusfertide, n=18; PBO, n=16), and 128 pts had normal BSL WBC (n=64 per arm).
From Wks 20–32, in the PHL only group, response rates were 84% (42/50) for rusfertide vs 29% (15/51) for PBO in pts with high PLT (common odds ratio [OR] 14.4; p<0.0001), and 73% (11/15) vs 47% (7/15) in pts with normal PLT (OR 3.3; p=0.1); response rates were 81% (21/26) for rusfertide vs 16% (5/31) for PBO in pts with high WBC (OR 21.8; p<0.0001) and 82% (32/39) vs 49% (17/35) in pts with normal WBC (OR 5.8; p=0.001). In the PHL+CRT group, response rates with rusfertide vs PBO were 65% (13/20) vs 55% (12/22) in pts with high PLT (OR 1.4; p=0.6) and 76% (47/62) vs 24% (14/58) in pts with normal PLT (OR 10.2; p<0.0001); response rates were 67% (12/18) for rusfertide vs 38% (6/16) for PBO in pts with high WBC (OR 4.4; p=0.06) and 75% (48/64) vs 31% (20/64) in pts with normal WBC (OR 5.7; p<0.0001).
In the PHL only group, mean (standard deviation [SD]) number of PHLs was 0.5 (1.2) for rusfertide vs 1.8 (1.5) for PBO in pts with high PLT (p<0.0001), and 0.4 (0.8) vs 1.5 (1.8) in pts with normal PLT (p=0.009); mean (SD) number of PHLs for rusfertide vs PBO was 0.3 (0.8) vs 2.2 (1.8) in pts with high WBC (p<0.0001), and 0.6 (1.2) vs 1.3 (1.2) in pts with normal WBC (p=0.0006). In the PHL+CRT group, mean (SD) number of PHLs for rusfertide vs PBO was 1.0 (2.1) vs 1.2 (1.2) in pts with high PLT (p=0.1), and 0.4 (0.7) vs 2.1 (1.5) in pts with normal PLT (p<0.0001); mean (SD) number of PHLs was 0.4 (0.9) for rusfertide vs 1.5 (1.2) for PBO in pts with high WBC (p=0.01), and 0.4 (0.9) vs 2.0 (1.5) in pts with normal WBC (p<0.0001).
In the PHL only group, 68% (34/50) of rusfertide vs 16% (8/51) of PBO pts with high PLT maintained Hct <45% (p<0.0001) while 53% (8/15) vs 13% (2/15) of pts with normal PLT (p=0.02) maintained Hct <45%; 69% (18/26) of rusfertide vs 13% (4/31) of PBO pts with high WBC maintained Hct <45% (p<0.0001), while 62% (24/39) vs 17% (6/35) (p<0.0001) of pts with normal WBC maintained Hct <45%. In the PHL+CRT group, 55% of rusfertide (11/20) vs 23% (5/22) of PBO pts with high PLT (p-value not calculable [NC]) maintained Hct <45%, while 63% (39/62) vs 10% (6/58) of pts with normal PLT (p<0.0001) maintained Hct <45%; 50% (9/18) vs 6% (1/16; p-value NC) of pts with high WBC, and 64% (41/64) vs 16% (10/64) (p<0.0001) of pts with normal WBC maintained Hct <45%. A limitation of the results was the small pt numbers in some subgroups.
Conclusions: In this post hoc analysis, rusfertide improved response rates and reduced PHL burden vs PBO in pts with PV, irrespective of BSL PLT or WBC counts, including those with concurrent thrombocytosis and/or leukocytosis. These findings support efficacy of rusfertide for Hct control across pts with PV.
DISCLOSURES
Andrew T Kuykendall, MD: Novartis - Honoraria; Incyte - Honoraria; Karyopharm - Honoraria; Disc Medicine - Honoraria; GlaxoSmithKline - Honoraria; Geron - Honoraria; Cogent - Honoraria; Bristol Myers Squibb - Honoraria; Blueprint - Honoraria; PharmaEssentia - Honoraria; Sobi - Honoraria; Kartos/Ipsen - Research Funding; Geron - Research Funding; Incyte - Research Funding; Blueprint - Research Funding; Protagonist - Research Funding; Novartis - Research Funding; AJAX/Eli Lilly - Research Funding; GlaxoSmithKline - Research Funding; Prelude - Research Funding; Bristol Myers Squibb - Research Funding; Takeda - Research Funding; Dompei - Research Funding; Janssen - Research Funding; Disc Medicine - Research Funding; AbbVie - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); Agios - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Disc Medicine - Consultancy (Includes expert testimony); Protagonist - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Calytrix - Consultancy (Includes expert testimony); Damora - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Silence Therapeutics - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony)